Imunon reports 2022 net loss of $35.9M ($5.03/share); cash $38.9M funds into 2025

Imunon, Inc.

Net loss $35.9M vs $20.8M in 2021; operating expenses up 18% to $25.4M.
Non-cash impairment charge of $13.4M on IPR&D asset; $4.5M interest from preferred stock redemption.
Cash $38.9M at year-end; expects to fund operations into 2025.
OVATION 2 study fully enrolled; Phase 1/2 with bevacizumab opened.
PLACCINE NHP data shows comparable protection to mRNA; stability >9 months at 4°C.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Imunon, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.